BTIG upgrades ImmunityBio with Buy rating and $13 price target. The biotech firm cited strong 2026 ANKTIVA sales growth, EU conditional marketing authorization, and Saudi Arabia NSCLC approval as key catalysts. ImmunityBio completed manufacturing programs for its natural killer cell therapy platform, with Phase 1 data showing the M-ceNK plus ANKTIVA combination was well-tolerated in cancer patients. Seventy-four participants enrolled across programs with no serious adverse events reported in treatment. The company's commercial-stage immunotherapy platform targets cancer and infectious diseases, positioning itself for potential multi-indication expansion as ANKTIVA gains regulatory approvals globally.
